Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting Triple-negative Breast Cancer or ER-positive, PR Positive her2 Negative by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial

NCT05957939 is registered in ClinicalTrials.gov with Ministry of Health, Saudi Arabia as lead sponsor.

NCT NCT05957939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05957939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting Triple-negative Breast Cancer or ER-positive, PR Positive her2 Negative by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial
Lead sponsor
Ministry of Health, Saudi Arabia
Phase
Phase 1
Overall status
Unknown status
Start date
January 1, 2024
Completion date
December 31, 2024
Enrollment
2 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

tnbc - triple-negative breast cancer